13 4月 2020 by admin in UncategorizedComments NextCure Provides Update on Clinical Trial Activities Due to Impact of COVID-19 Pandemic
20 3月 2020 by admin in UncategorizedComments Design Therapeutics Launches with $45 Million to Develop a New Class of Disease-Modifying Therapies for Serious Degenerative Disorders
20 3月 2020 by admin in UncategorizedComments Design Therapeutics Launches with $45 Million to Develop a New Class of Disease-Modifying Therapies for Serious Degenerative Disorders
12 3月 2020 by admin in UncategorizedComments resTORbio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
12 3月 2020 by admin in UncategorizedComments NextCure Reports Fourth Quarter and Full Year 2019 Financial Results
12 3月 2020 by admin in UncategorizedComments Arcellx Announces FDA Orphan Drug Designation for CART-ddBCMA for the Treatment of Multiple Myeloma
28 2月 2020 by admin in UncategorizedComments Arcellx Announces First Patient Treated with T Cell Therapy Utilizing the Company’s Novel Binding Domain
30 1月 2020 by admin in UncategorizedComments TEMPEST THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR TPST-1495 AND WELCOMES NEW INVESTORS
20 12月 2019 by admin in UncategorizedComments Syros Announces Appointment of Mark Alles to Its Board of Directors
18 12月 2019 by admin in UncategorizedComments GBT and Syros Partner to Discover, Develop and Commercialize Novel Therapies for Sickle Cell Disease and Beta Thalassemia
03 12月 2019 by admin in UncategorizedComments Centrexion Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lead Pipeline Candidate CNTX-4975
15 11月 2019 by admin in UncategorizedComments resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary Endpoint
14 11月 2019 by admin in UncategorizedComments NextCure Announces Pricing of Public Offering of Common Stock
12 11月 2019 by admin in UncategorizedComments Syros Reports Third Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
12 11月 2019 by admin in UncategorizedComments NextCure Announces Proposed Public Offering of Common Stock
09 11月 2019 by admin in UncategorizedComments NextCure Presents Updated Clinical Data from NC318 Phase 1/2 Clinical Trial at the 34th Annual Meeting of Society for Immunotherapy of Cancer (SITC) and Announces Initiation of Phase 2 Portion of the Trial
08 11月 2019 by admin in UncategorizedComments Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 American College of Rheumatology Annual Meeting and the 2019 American Academy of Physical Medicine and Rehabilitation Annual Assembly
05 11月 2019 by admin in UncategorizedComments Syros to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
05 11月 2019 by admin in UncategorizedComments resTORbio Reports Third Quarter 2019 Financial Results and Corporate Update
04 11月 2019 by admin in UncategorizedComments NextCure to Host and Webcast Event at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
25 10月 2019 by admin in UncategorizedComments New Biotechnology publication validates Crescendo Biologics’ platform as it moves towards the clinic
17 10月 2019 by admin in UncategorizedComments Syros Announces Update on Selective CDK7 Inhibitor Portfolio
07 10月 2019 by admin in UncategorizedComments Tempest Therapeutics Names Biopharmaceutical Executive Stephen Brady as President and Chief Operating Office
03 10月 2019 by admin in UncategorizedComments Arcellx Raises $85 Million in a Series B Financing to Advance its Intelligent Cell Therapy Platform
02 10月 2019 by admin in UncategorizedComments NextCure Announces Promotion of Timothy Mayer, Ph.D., to Chief Operating Officer
24 9月 2019 by admin in UncategorizedComments Crescendo Biologics Reaches Fifth Milestone in its Strategic Collaboration with Takeda
12 9月 2019 by admin in UncategorizedComments Crescendo Biologics to collaborate with world-leading oncology groups at the University of Oxford and the University of Surrey
05 9月 2019 by admin in UncategorizedComments Crescendo Biologics strengthens leadership team with appointment of ex-GSK Stewart Kay, as Chief Business Officer
04 9月 2019 by admin in UncategorizedComments Centrexion Therapeutics Announces CNTX-4975, CNTX-6970 and CNTX-6016 Data Presentations at PAINWeek 2019 National Conference
01 8月 2019 by admin in UncategorizedComments Syros Reports Second Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
25 7月 2019 by admin in UncategorizedComments Syros to Report Second Quarter 2019 Financial Results on Thursday, August 1, 2019
23 7月 2019 by admin in UncategorizedComments resTORbio Announces Early Completion of Enrollment of Phase 3 PROTECTOR 1 Trial with RTB101 in Clinically Symptomatic Respiratory Illness
23 7月 2019 by admin in UncategorizedComments Crescendo Biologics’ second oncology-targeted Humabody® licensed by Takeda
05 6月 2019 by admin in UncategorizedComments Centrexion Therapeutics Announces Completion of Patient Enrollment in Pivotal Clinical Trial of Repeat Doses of CNTX-4975 in Patients with Moderate to Severe Osteoarthritis Knee Pain
31 5月 2019 by admin in UncategorizedComments Crescendo Biologics Announces Prestigious Academic Research Collaborations
28 5月 2019 by admin in UncategorizedComments Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics
24 5月 2019 by admin in UncategorizedComments Crescendo Biologics Achieves Another Milestone in its Strategic Collaboration with Takeda
